Cemacabtagene ansegedleucel, an allogeneic chimeric antigen receptor (CAR) T-cell therapy, is being investigated in relapsed/refractory large B-cell lymphoma. The investigational allogeneic chimeric ...
The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and safety in non-Hodgkin lymphoma treatment. This exchange appears in the ...
Receptors on B and T cells hint at what the immune system is targeting. An AI approach called Mal-ID developed increases diagnostic accuracy, particularly for autoimmune diseases. Your immune system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results